Uncategorized Archives - Page 41 of 145

ThursdayDec 22, 2022 12:00 pm

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

CNS Pharmaceuticals is a biopharmaceutical company that focuses on developing novel treatments for primary and metastatic cancers in the brain and central nervous system The company is currently evaluating the efficacy of Berubicin, a novel anthracycline that appears to cross the blood-brain barrier, in a potentially pivotal Phase 2 trial involving patients with recurrent glioblastoma multiforme (“GBM”) CEO John Climaco recently participated in the Virtual Investor “Ask the CEO” Event in which he provided an update on recent key events and plans for the future in addition to allaying the investors’ concerns regarding the recent reverse stock split CNS Pharmaceuticals…

WednesdayDec 21, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

BEAT has developed technology that collects data to synthesize a 12-lead 3D vector electrocardiogram (“VECG”) The device provides physicians with a 12-lead ECG associated with chest pain compared to a baseline ECG for the patient This key data enables physicians to assess whether symptoms may be the result of a heart attack HeartBeam’s (NASDAQ: BEAT) small, portable, easy-to-use heart-attack detection solution was the focus of a recent Big Biz Show episode; the Big Biz Show features fast-talking, hard-hitting discussions on business and finance. During the interview, Big Biz Show host Bob “Sully” Sullivan chatted with HeartBeam founder and CEO Branislav…

TuesdayDec 20, 2022 11:15 am

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

Jupiter Wellness has announced that the “FDA of India” has approved its topical treatment for psoriasis and vitiligo, with a market launch to follow The global vitiligo treatment market was valued at $1.2 billion in 2018 and is expected to grow at a CAGR of 5.8%, resulting in a value of approximately $2 billion by 2026 JW-500, a topical treatment for female sexual wellness, is currently in development with plans to file for pre-IND and Orphan Drug Designation within the next year Jupiter Wellness (NASDAQ: JUPW), a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”)…

MondayDec 19, 2022 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection

BEAT continues impressive march forward in developing a suite of products designed to detect heart attacks anytime, anywhere Inventions protected by patent enable proprietary 3D vector ECG technology to be built into a smartwatch Projections for global smartwatch and wearables medical-device markets show consistent upward growth In a world where an estimated 202.6 million people use smartwatches (https://ibn.fm/zb66P), the ability to harness the power of smartwatches to help people live healthier lives can make a profound difference. That’s exactly what HeartBeam (NASDAQ: BEAT), a cardiac technology company with a track record for innovation and cutting-edge technology, hopes to do with…

FridayDec 16, 2022 12:00 pm

Jupiter Wellness Inc. (NASDAQ: JUPW) Is ‘One to Watch’

Jupiter Wellness’s product pipeline addresses a range of underserved conditions, including hair loss, eczema, burns, and sexual wellness The company’s revenue is generated through OTC and consumer product sales, contract research agreements, and licensing royalties Jupiter Wellness recently announced that it has been approved to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs Jupiter Wellness (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary…

FridayDec 16, 2022 11:15 am

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

Ludlow Research ups price target for MetAlert, leading developer of location-sensitive health monitoring devices and wearable technology products, anticipating target between $1 and $1.25 per share MetAlert announced the elimination of all its toxic convertible notes from its balance sheet, which now provides increased stability to its public float The company also shared improved guidance to its NFC operations while also announcing the launch of new medical devices geared toward the geriatric and autism healthcare markets Q4 2022 also saw the influx of new chips, which will significantly increase production of the company’s SmartSole units in early 2023, ramp up…

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials…

TuesdayDec 13, 2022 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025 A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid…

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels CNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and Europe Berubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan…

FridayDec 09, 2022 9:00 am

MetAlert Inc. (MLRT) to Begin Marketing and Distribution of RoomMate(TM) in the U.S., Canada, and the U.K., following Partnership with Sensio Group

MetAlert recently announced the signing of an LOI with Sensio Group for the marketing and distribution of RoomMate, a 3D Infrared supervision product with a fall detection automated monitoring system The company has set out to solve problems unique to individuals afflicted with ADA by creating devices specific to their use cases, and RoomMate is one such product, promising effective remote patient monitoring while maintaining anonymity Through this partnership, MetAlert looks to penetrate the high CAGR projected patient monitoring devices market, valued at $47 billion in 2021 It also looks to leverage the partnership for future up-listing onto a major…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Updates of Recent Key Events and Plans for Calendar 2023; Announces Public Offering to Raise Funding for Operations

HeartBeam Inc. (NASDAQ: BEAT) CEO Featured Guest on Big Biz Show, Talks ‘Breakthrough’ Heart-Attack Detection Technology

Jupiter Wellness Inc. (NASDAQ: JUPW) Issues Letter to Shareholders with Update on Key Corporate Milestones, Product Progress

HeartBeam Inc. (NASDAQ: BEAT) Granted Patent for Proprietary ECG Smartwatch-Based Monitor Designed for Heart Attack Detection

Jupiter Wellness Inc. (NASDAQ: JUPW) Is ‘One to Watch’

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

MetAlert Inc. (MLRT) to Begin Marketing and Distribution of RoomMate(TM) in the U.S., Canada, and the U.K., following Partnership with Sensio Group

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search